wherein R is lower-alkyl, R^1 is halogen, R^2 is C_1-C_{12}-alkyl, R^3 is hydroxy, lower-alkoxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy, lower-alkylaminocarbonyloxy; or arylaminocarbonyloxy or aryl-lower-alkylaminocarbonyloxy, wherein aryl is phenyl or ~~optionally~~ phenyl mono- or multiply-substituted by halogen, trifluoromethyl, lower-alkyl, lower-alkoxy, nitro or amino; X is C_1-C_{18}-alkylene which ~~optionally~~ can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo-[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dion-10-yl and n is number 0 or 1,

in the form of a racemate or an optical antipode, an N-oxide, or a pharmaceutically usable acid addition salt thereof.

~~23.~~ 16. A composition with calcium antagonistic activity comprising a calcium antagonistically effective amount of a compound of the formula



I

wherein R is lower-alkyl, R^1 is halogen, R^2 is C_1-C_{12}-alkyl, R^3 is hydroxy, lower-alkoxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy, lower-alkylaminocarbonyloxy; or arylaminocarbonyloxy or aryl-lower-alkylaminocarbonyloxy, wherein aryl is phenyl or phenyl ~~optionally~~ mono- or multiply-substituted by halogen, trifluoromethyl, lower-alkyl, lower-alkoxy, nitro or amino; ~~or~~ X is C_1-C_{18}-alkylene which ~~optionally~~ can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo-[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dion-10-yl and n is the number 0 or 1,

in the form of a racemate or an optical antipode, an N-oxide, or a pharmaceutically usable acid addition salt thereof, and a pharmaceutically inert excipient.

~~24.~~ 19. A method of treating or preventing angina pectoris, ischaemia, arrhythmias, high blood pressure and cardiac insufficiency which comprises administering to a warm-blooded animal in need of such treatment, a calcium antagonistically effective amount of a compound of the formula



I

wherein R is lower-alkyl, R^1 is halogen, R^2 is C_1-C_{12}-alkyl, R^3 is hydroxy, lower-alkoxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy, lower-alkylaminocarbonyloxy; or, arylaminocarbonyloxy or aryl-lower-alkylaminocarbonyloxy, wherein aryl is phenyl ~~optionally~~ or phenyl mono- or multiply-substituted by halogen, trifluoromethyl, lower-alkyl, lower-alkoxy, nitro or amino; X is C_1-C_{18}-alkylene which ~~optionally~~ can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dion-10-yl and n is the number 0 or 1,

in the form of a racemate or an optical antipode, an N-oxide, or a pharmaceutically usable acid addition salt thereof.

Please amend claims 2, 5, 6, 7, 8, 10, 12, 13, 14 and 15 by deleting in line 1 "claim 1" and inserting therefor, -- claim 22 --.

Please amend claim 17, line 1 by deleting "claim 16" and inserting therefor -- claim 23 --.